Mentioned:
ATAI -12.33% CUPR -1.92%
Christian Angermayer is a big believer in the future of psychedelic medicines. Which is exactly why he’s pouring tens of millions of dollars into acquiring more of atai Life Sciences.
What’s happening:
- Christian Angermayer has publicly disclosed he has purchased $19M USD worth of common shares in atai Life Sciences (NASDAQ: ATAI) through new filings made with the United States Securities and Exchange Commission
By the numbers:
- Christian Angermayer purchased roughly 8.6M common shares of atai Life Sciences at a price of $2.19 USD per share
- The new purchase brings Christian Angermayer’s total equity stake in atai Life Sciences to more than 51M common shares
Why it matters:
- atai Life Sciences recently made waves on Wall Street when they merged with private psychedelic drug discovery company Beckley Psytech in a new all stock deal to acquire their intellectual property and pipeline of novel psychedelic therapeutics
Going deeper:
- Christian Angermayer has been making a flurry of new investments into both private and public companies lately through his family office Apeiron Investments, including backing tokenized uranium startup Uranium Digital and copper exploration company Super Copper (CSE: CUPR)
